Ключевые слова:
alpha galactosidase; biological marker; globotriaosylsphingosine; unclassified drug; alpha galactosidase; cerebrovascular accident; clinical effectiveness; clinical practice; cost benefit analysis; disease association; end stage renal disease; enzyme activity; enzyme replacement; Fabry disease; GLA gene; health; health economics; health hazard; heart left ventricle hypertrophy; hemodialysis; human; hypertrophic cardiomyopathy; Letter; practice guideline; screening; sensitivity and specificity; sex difference; unexplained left ventricle hypertrophy; wellbeing; Fabry disease; heart left ventricle hypertrophy; alpha-Galactosidase; Cost-Benefit Analysis; Fabry Disease; Humans; Hypertrophy, Left Ventricular
Moiseev S. V. Sergej Valentinovich 1960-
Tao E. A. Ekaterina Aleksandrovna 1993-
Moiseev A.
Bulanov N. M. Nikolay Mikhaylovich 1988-
Fomin V. V. Viktor Viktorovich 1978-
Моисеев С. В. Сергей Валентинович 1960-
Тао Е. А. Екатерина Александровна 1993-
Моисеев А.
Буланов Н. М. Николай Михайлович 1988-
Фомин В. В. Виктор Викторович 1978-
Strategies of Screening for Fabry Disease in Patients with Unexplained Left Ventricular Hypertrophy
Текст визуальный непосредственный
Mayo Clinic Proceedings
Dowden Health Media, Inc.
Vol.94, Issue8 P. 1644-1646
2019
Письмо
alpha galactosidase biological marker globotriaosylsphingosine unclassified drug alpha galactosidase cerebrovascular accident clinical effectiveness clinical practice cost benefit analysis disease association end stage renal disease enzyme activity enzyme replacement Fabry disease GLA gene health health economics health hazard heart left ventricle hypertrophy hemodialysis human hypertrophic cardiomyopathy Letter practice guideline screening sensitivity and specificity sex difference unexplained left ventricle hypertrophy wellbeing Fabry disease heart left ventricle hypertrophy alpha-Galactosidase Cost-Benefit Analysis Fabry Disease Humans Hypertrophy, Left Ventricular
[краткое описание не найдено]